Versor Investments LP Purchases 3,000 Shares of Inari Medical, Inc. (NASDAQ:NARI)

Versor Investments LP raised its holdings in shares of Inari Medical, Inc. (NASDAQ:NARI) by 31.3% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 12,600 shares of the company’s stock after buying an additional 3,000 shares during the period. Versor Investments LP’s holdings in Inari Medical were worth $643,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently modified their holdings of the company. R Squared Ltd bought a new position in shares of Inari Medical during the fourth quarter valued at about $45,000. KBC Group NV grew its stake in shares of Inari Medical by 39.0% during the third quarter. KBC Group NV now owns 1,774 shares of the company’s stock valued at $73,000 after buying an additional 498 shares during the last quarter. GAMMA Investing LLC grew its stake in shares of Inari Medical by 66.8% in the fourth quarter. GAMMA Investing LLC now owns 1,963 shares of the company’s stock worth $100,000 after purchasing an additional 786 shares during the last quarter. Covestor Ltd grew its stake in shares of Inari Medical by 63.5% in the third quarter. Covestor Ltd now owns 2,384 shares of the company’s stock worth $99,000 after purchasing an additional 926 shares during the last quarter. Finally, Point72 Asia Singapore Pte. Ltd. grew its stake in shares of Inari Medical by 44.2% in the third quarter. Point72 Asia Singapore Pte. Ltd. now owns 3,113 shares of the company’s stock worth $128,000 after purchasing an additional 954 shares during the last quarter. 90.98% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

NARI has been the topic of several recent analyst reports. Robert W. Baird reissued a “neutral” rating and issued a $80.00 target price (down from $81.00) on shares of Inari Medical in a research note on Tuesday, January 7th. BTIG Research reissued a “neutral” rating on shares of Inari Medical in a research note on Wednesday, January 8th. Oppenheimer began coverage on Inari Medical in a research note on Tuesday, December 17th. They issued an “outperform” rating and a $75.00 target price on the stock. Wells Fargo & Company reaffirmed an “equal weight” rating and set a $80.00 price objective (up from $65.00) on shares of Inari Medical in a research report on Tuesday, January 7th. Finally, Baird R W cut Inari Medical from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, January 7th. Twelve investment analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and an average price target of $68.00.

Insider Buying and Selling at Inari Medical

In related news, CEO Andrew Hykes sold 3,000 shares of the company’s stock in a transaction on Friday, December 20th. The shares were sold at an average price of $55.29, for a total value of $165,870.00. Following the completion of the transaction, the chief executive officer now owns 439,310 shares of the company’s stock, valued at approximately $24,289,449.90. This represents a 0.68 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, Director William Hoffman sold 60,000 shares of the company’s stock in a transaction on Monday, December 16th. The stock was sold at an average price of $55.66, for a total transaction of $3,339,600.00. Following the completion of the transaction, the director now directly owns 441,233 shares of the company’s stock, valued at $24,559,028.78. This represents a 11.97 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 263,000 shares of company stock worth $15,599,470. Insiders own 10.60% of the company’s stock.

Inari Medical Stock Performance

Shares of NARI opened at $79.97 on Friday. The firm has a market cap of $4.68 billion, a PE ratio of -59.24 and a beta of 1.02. The firm has a fifty day simple moving average of $73.44 and a two-hundred day simple moving average of $56.31. Inari Medical, Inc. has a 1-year low of $36.73 and a 1-year high of $79.99.

About Inari Medical

Inari Medical, Inc builds minimally invasive, novel, and catheter-based mechanical thrombectomy devices and accessories for the specific disease states in the United States. The company provides ClotTriever system, which is designed to core, capture, and remove large clots from large vessels for treatment of deep vein thrombosis and peripheral thrombus; FlowTriever system, a large bore catheter-based aspiration and mechanical thrombectomy system to remove large clots from large vessels in the peripheral vasculature for treating pulmonary embolism and other complex venous thromboembolism cases; InThrill system to treat small vessel thrombosis; and LimFlow system for patients who have chronic limb-threatening ischemia with no suitable endovascular or surgical revascularization options and risk of major amputation.